

# Finix®

Rabeprazole Sodium BP

**Description:** Rabeprazole Sodium (Finix®) is an antiulcerant drug in the class of Proton Pump Inhibitor.

**Pharmacokinetics:** Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H<sup>+</sup>/K<sup>+</sup>-ATPase enzyme at the secretory surface of the gastric parietal cell. Rabeprazole is absorbed and can be detected in plasma by 1 hour. The effects of food on the absorption of Rabeprazole have not been evaluated. Rabeprazole is 96.3% bound to human plasma proteins. Approximately 90% of Rabeprazole is eliminated in the urine. The remainder of the dose is excreted in the feces.

**Composition:**

**Finix® 20 mg Tablet:** Each enteric coated tablet contains Rabeprazole Sodium BP 20 mg.

**Finix® 10 mg Capsule:** Each delayed release sprinkle capsule contains Rabeprazole Sodium BP 10 mg.

**Finix® 20 mg Capsule:** Each delayed release capsule contains Rabeprazole Sodium BP 20 mg.

**Indications:**

- Healing of erosive or ulcerative Gastro Esophageal Reflux Disease (GERD)
- Maintenance of healing of erosive or ulcerative Gastro Esophageal Reflux Disease (GERD)
- Treatment of Symptomatic GERD
- Healing of Gastric & Duodenal Ulcers
- Long-term treatment of pathological hyper secretory conditions, including Zollinger-Ellison Syndrome.
- In combination with Amoxicillin and Clarithromycin to eradicate *Helicobacter pylori*.

**Dosage & administration:**

| Disease  | Dosage & Frequency | Treatment duration   |
|--|--------------------|--|
| Healing of erosive or ulcerative Gastro Esophageal Reflux Disease (GERD)                   | 20 mg once daily   | 4 to 8 weeks; patients have not healed after 8 weeks of treatment, an additional 8 week course may be considered.  |
| Maintenance of healing of erosive or ulcerative GERD                                       | 20 mg once daily   |  |
| Treatment of Symptomatic GERD  | 20 mg once daily   | 4 weeks; If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. |
| Healing of Duodenal Ulcer  | 20 mg once daily   | 4 weeks; If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. |
| Treatment of Pathological Hyper secretory Conditions, including Zollinger-Ellison Syndrome | 60 mg once daily   | Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated.      |
| Treatment of GERD in pediatric patients 1 to 11 years of age (Less than 15 kg)             | 5 mg once daily    | 12 weeks with the option to increase to 10 mg if inadequate response.  |
| Treatment of GERD in pediatric patients 1 to 11 years of age (15 kg or more)               | 10 mg once daily   | 12 weeks.  |

রাবেপ্রাজল সোডিয়াম

২০ মিগ্রা

১০০০ মিগ্রা

৫০০ মিগ্রা

১০ মিগ্রা